Bifidobacterium breve 관련 Irritable Bowel Syndrome (IBS)
DLimited data from small studies. Preliminary evidence for symptom improvement.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbifidobacterium\u002Dbreve\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
결론
Limited data from small studies. Preliminary evidence for symptom improvement.
Key Study Findings
Review
Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases.
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: None
Other
n=1098
8 weeks
Open-label
A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of …
Dose: None
vs: None (single-arm open-label)
Outcome: Treatment success for abdominal pain and bloating
효과: 73% pain, 81.9% bloating success at T1
<0.001
대상 집단: IBS patients from 52 Italian gastroenterologists
Randomized Controlled Trial
n=61
8 weeks
Double-blind
Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with …
Dose: None
vs: Placebo
Outcome: IBS-SSS symptom severity score change
효과: None
None
대상 집단: Patients with moderate-severe diarrhea-predominant IBS
Randomized Controlled Trial
4 weeks
Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …
Dose: 2 g
vs: Placebo
Outcome: Constipation symptoms
효과: None
P = 0.005
대상 집단: IBS patients
Review
Postbiotics: A new member in the biotics family.
Dose: None
vs: None
Outcome: Clinical applications overview
효과: None
None
대상 집단: General population (review)
In Vitro
Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal …
Dose: None
vs: None
Outcome: Colitis severity
효과: None
None
대상 집단: Crohn's disease patients
Key Statistics
2
연구
150
참여자
↑
Positive
D
등급
Referenced Papers
Microbiome research reports
2025
16 인용
Beneficial microbes
2025
Frontiers in nutrition
2025
The Yale journal …
2024
5 인용
Journal of neurogastroenterology …
2024
4 인용
Archivos argentinos de …
2024
3 인용
Cureus
2024
1 인용
Journal of translational …
2023
30 인용
Nutrients
2023
19 인용
Journal of neurogastroenterology …
2022
21 인용
Journal of microbiology …
2022
15 인용
Scientific reports
2022
14 인용
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review.
Systematic Review
Journal of clinical …
2018
34 인용
Journal of clinical …
2015
62 인용
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis.
Meta-Analysis
Revista espanola de …
2013
102 인용
Journal of clinical …
2012
207 인용
PloS one
2012
31 인용
Beneficial microbes
2011
89 인용
The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat.
Other
Neurogastroenterology and motility
2010
213 인용
BMC gastroenterology
2010
91 인용
Alimentary pharmacology & …
2007
102 인용
Asia Pacific journal …
2006
Alimentary pharmacology & …
2005
398 인용
Journal of clinical …
2004
205 인용
Research in microbiology
2001
201 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 1-10 billion CFU/day
- adultgisupport:
- 5-10 billion CFU/day
- neonatalsupport:
- 1-5 billion CFU/day (as directed by pediatrician)
상한량: Well-tolerated up to 10 billion CFU/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | 8 weeks | Positive | 1098 |
| None | 8 weeks | Neutral | 61 |
| 2 g | 4 weeks | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| Serum-derived bovine immunoglobulin (SBI) | -- | Positive | -- |
| None | -- | Positive | -- |
권장 복용 시간: Before meals or on empty stomach; for infants, mix with breast milk or formula
Safety & Side Effects
보고된 부작용
- ⚠ Mild gas during initial use
- ⚠ Occasional loose stools in infants (transient)
- ⚠ Rare abdominal discomfort
- ⚠ Very rare: bacteremia in immunocompromised individuals
알려진 상호작용
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (use with caution in immunocompromised patients)
일일 최대 섭취 허용량: Well-tolerated up to 10 billion CFU/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does Bifidobacterium breve help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Bifidobacterium breve may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).
How much Bifidobacterium breve should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium breve?
Reported side effects may include Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium breve and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Irritable Bowel Syndrome (IBS)
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.